By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

AmpliPhi Biosciences (Formerly known as Targeted Genetics) 

4870 Sadler Road
Suite 300
Glen Allen  Virginia  23060  U.S.A.
Phone: 804-205-5069 Fax: 206-223-0288


SEARCH JOBS
AmpliPhi Biosciences is a biopharmaceutical company focused on the development of an internally generated pipeline of naturally occurring viruses called bacteriophage (phage) for the treatment of bacterial infection. Phage-based therapy provides a unique and proven approach to treating a wide variety of bacterial infections and in particular, drug-resistant strains of bacteria that are commonly found in the hospital setting. We have built a drug development and manufacturing platform designed to allow rapid development and production of multiple phage-based therapies. Our plan and success relies on our ability to identify and develop selected phage to eradicate targeted bacterial infections across a wide range of bacterial disease. Initially our phage discovery and development platform will focus efforts in acute and chronic lung, sinus and gastrointestinal (GI) infections.

AmpliPhi maintains operations in Richmond, Virginia in the United States, in Colworth Science Park, near London in the United Kingdom, and outside Sydney, NSW, Australia.


Key Statistics


Email: n/a
Ownership: Public

Web Site: AmpliPhi Bio
Employees:
Symbol: APHB
 





Collaborations

Collateral Therapeutics Inc.  Vector-licensing agreement for the potential treatment of congestive heart failure.





Company News
AmpliPhi Bio (APHB) To Be Granted European Patent Covering The Use Of Phage Therapy To Resensitize Bacterial Infections To Antibiotics 6/2/2016 10:48:08 AM
BIO2016: AmpliPhi Bio (APHB)’s CEO To Discuss Novel Approaches To Fighting Drug-Resistant Pathogens In Panel At BIO International 5/31/2016 11:16:56 AM
AmpliPhi Bio (APHB) Announces Start Of First Phage Therapy Trial In U.S. Under IND 5/24/2016 10:16:08 AM
AmpliPhi Bio (APHB) Reports First Quarter 2016 Financial Results And Provides Corporate Update 5/13/2016 9:25:42 AM
AmpliPhi Bio (APHB) Provides Update On Phase I Trial: Phage Therapy Well Tolerated In First Cohort 4/20/2016 11:19:23 AM
AmpliPhi Bio (APHB) Abandons Deal with Intrexon 4/14/2016 7:12:51 AM
AmpliPhi Biosciences Corporation (APHB) Presents Data Showing Bacteriophage Product Candidate Kills Pseudomonas Aeruginosa Isolates From Cystic Fibrosis Patients 4/13/2016 10:25:35 AM
AmpliPhi Biosciences Corporation (APHB) Announces Conversion Of all Series B Redeemable Preferred Stock Into Common Stock 4/11/2016 12:38:17 PM
AmpliPhi Biosciences Corporation (APHB) Reports Full-Year 2015 Financial Results 3/31/2016 9:19:30 AM
AmpliPhi Biosciences Corporation (APHB) To Host Full-Year 2015 Financial Results Conference Call And Webcast On March 30, 2016 3/29/2016 10:25:22 AM
12345678910...
//-->